Safety and tolerability of pioglitazone

Summary:

Pioglitazone HCl, a new thiazolidinedione (TZD), has been developed for the treatment of type 2 diabetes. The drug was tested in several trials that included over 5,000 subjects. Of these, over 3,500 subjects received active treatment. At doses between 15-45 mg pioglitazone was well tolerated with dropouts due to adverse events being similar in pioglitazone and placebo groups. The main side effect of treatment was mild to moderate peripheral oedema. Oedema was not associated with signs or symptoms of congestive cardiac failure, and there was no excess of adverse events in the cardiovascular system in the pioglitazone-treated patients. Weight increases were seen during treatment with pioglitazone, with most weight gain in the early period of the treatment, which then stabilised. It has been shown to be due to increases in subcutaneous fat. Despite weight gain, the favourable effects of pioglitazone on glycaemic control and lipids were maintained. In laboratory tests, small decreases in haemoglobin and haematocrit were seen due to haemodilution. However, anaemia was not reported more often with pioglitazone than with placebo and no patients were discontinued due to anaemia associated with pioglitazone. A thorough analysis of results of liver tests revealed no evidence of hepatotoxicity with pioglitazone. The safety profile of pioglitazone demonstrated by clinical trials is supported further by safety data from the market in USA and Japan, where the drug has been widely prescribed for over a year. A safety and tolerability profile, similar to that seen in clinical trials, has been reported.

Safety - pioglitazone - adverse event

References

• 1 Bonora E, Formentini G, Calcaterra F, Marini F, Muggeo M. Homeostasis model assessment of insulin resistance predicts cardiovascular disease in type 2 diabetes mellitus.  Diabetes 49 ((Suppl 1)) A21 2000; 
• 2 Day C. Thiazolidinediones: a new class of antidiabetic drugs.  Diabetic Med. 16 179-192 1999; 
• 3 DeFronzo R A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis.  Neth J Med. 50 191-197 1997; 
• 4 Despres J P. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk.  Obesity Res 6 ((Suppl 1)) p8S-17S 1998; 
• 5 Dougall H T. McLay J. A comparative review of the adverse effects of calcium antagonists.  Drug Saf. 15 91-106 1996; 
• 6 FDA Report Rezulin to be withdrawn from the market. HHS News, FDA 21.March.2000
• 7 Gitlin N, Julie N L, Spurr C L, Lim K N, Juarbe H M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.  Ann Intern Med. 129 36-38 1998; 
• 8 Haffner S M. Epidemiology of insulin resistance and its relation to coronary artery disease.  Am J Cardiol. 84 11J-14J 1999; 
• 9 Haffner S M, D'Agostino R, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage P J, Saad M F. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study.  Diabetes Care. 22 562-568 1999; 
• 10 Henry R R. Thiazolidinediones.  Endocrinol Metab Clin North Am. 26 553-573 1997; 
• 11 Hirshberg B, Muszkat M, Marom T, Shalit M. Natural course of insulin edema.  J Endocrinol Invest. 23 187-188 2000; 
• 12 Hsueh W A, Law R E. Cardiovascular risk continuum: implications of insulin resistance and diabetes.  Am J Med. 105 4S-14S 1998; 
• 13 Kawasaki H, Kuroda S, Mimaki Y. [Vascular effects of insulin] [In process citation].  Nippon Yakurigaku Zasshi. 115 287-294 2000; 
• 14 Keen H, Clark C, Laakso M. Reducing the burden of diabetes: Managing cardiovascular disease.  Diabetes Metab Rev. 15 186-196 1999; 
• 15 Kemnitz J W, Elson D F, Roecker E B, Baum S T, Bergman R N, Meglasson M D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.  Diabetes. 43 204-211 1994; 
• 16 Kinoshita J, Tanaka Y, Niwa M, Yoshii H, Takagi M, Kawamori R. Impairment of insulin-induced vasodilation is associated with muscle insulin resistance in type 2 diabetes.  Diabetes Res Clin Pract. 47 185-190 2000; 
• 17 Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Cusi K, Mandarino L, DeFronzo R A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).  Diabetes 49 ((Suppl 1)) A299 2000; 
• 18 Montague C T, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity.  Diabetes. 49 883-888 2000; 
• 19 Neuschwander-Tetri B A, Isley W L, Oki J C, Ramrakhiani S, Quiason S G, Phillips N J, Brunt E M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report.  Ann Intern Med. 129 38-41 1998; 
• 20 Ravi T S, Nelli P, Rai P, Kundaje G N. Insulin oedema: an uncommon complication of insulin therapy.  J Assoc Physicians India. 39 411-412 1991; 
• 21 Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis.  Diabetes Care. 21 2140-2143 1998; 
• 22 Stratton I M, Adler A I, Neil H A, Matthews D R, Manley S E, Cull C A, Hadden D, Turner R C, Holman R R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  Br Med J. 321(7258) 405-412 2000; 
• 23 UKPDS . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 352 837-853 1998a; 
• 24 UKPDS . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).  Br Med J. 317 703-713 1998b; 
• 25 Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone.  N Engl J Med. 338 916-917 1998;